The Shareholders Foundation announces that an investigation on behalf of investors, who currently hold shares of Catamaran Corp (USA) (NASDAQ:CTRX), was initiated concerning whether the takeover of Catamaran Corp by OptumRx is unfair to NASDAQ:CTRX stockholders.
Investors who purchased shares of Catamaran Corp (USA) (NASDAQ:CTRX) and currently hold any of those NASDAQ:CTRX shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain officers and directors of Catamaran Corp breached their fiduciary duties owed to NASDAQ:CTRX investors in connection with the proposed acquisition.
On March 30, 2015 OptumRx and Catamaran Corporation [NASDAQ: CTRX, TSX: CCT] announced they have agreed to combine. The agreement calls for the acquisition of Catamaran Corp (USA) (NASDAQ:CTRX) outstanding common stock for $61.50 per share in cash.
However, given that at least one analyst has set the high target price for NASDAQ:CTRX shares at $66.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:CTRX stockholders. More specifically, the investigation concerns whether the Catamaran Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
Catamaran Corp reported that its annual Total Revenue rose from over $4.97 billion in 2011 to over $21.58 billion in 2014 and that its respective Net Income increased from $91.79 million to $317.29 million.
On April 10, 2015, NASDAQ:CTRX shares closed at $59.61 per share.
Those who are current investors in Catamaran Corp (USA) (NASDAQ:CTRX) shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego